[EN] Background. Angiogenesis and lymphangiogenesis are key mechanisms for tumor growth and dissemination. They are mainly regulated by the vascular endothelial growth factor (VEGF) family of ligands and receptors. The aim ...
[EN] Tumors develop mechanisms to recruit tolerogenic immune cells and to induce the expression of molecules that act as immune checkpoints. This regulation of the immune microenvironment favors immune tolerance to the ...
[EN] Background: Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies including lung cancer. A soluble fragment of the EGFR extracellular domain (sEGFR) can be detected in the ...
Sirera Pérez, Rafael; Bremnes, Roy M.; Cabrera, Andrea; Jantus Lewintre, Eloisa; Sanmartin, Elena; Blasco, Ana; del Pozo, Nieves; Rosell, Rafael; Guijarro, Ricardo; Galbis, Jose; Sanchez, Jose Javier; Camps, Carlos(Lippincott, Williams & Wilkins, 2011-02)
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than in controls. Qualitative and quantitative analysis of circulating DNA is a promising noninvasive tool. Our aim was to ...
Introduction: The vascular endothelial growth factor (VEGF) family of ligands and receptors (VEGFR) play an important role in tumor angiogenesis. Increased expression of angiogenic factors in tumors or in blood is associated ...
[EN] The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have ...
[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans ...
[EN] In May 2007, the Consorcio Hospital General Universitario de Valencia created the position of "Liaison Oncologist". The holder of this position is responsible for coordinating specialised and primary hospital care in ...
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...
[EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth ...
Jantus-Lewintre, Eloisa; Massuti Sureda, Bartomeu; Gonzalez Larriba, Jose Luis; Rodríguez-Abreu, Delvys; Juan, Oscar; Blasco, Ana; Domine, Manuel; Provencio Pulla, Mariano; Garde, Javier; Alvarez, Rosa; Maestu, Inmaculada; Perez de Carrion, Ramon; Artal, Angel; Rolfo, Christian; de Castro, Javier; Camps, Carlos(Frontiers Media SA, 2021-07-26)
[EN] Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes ...
Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical ...